BreakingModels

Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

Glass Epoch DeskOriginal digestSource: TechCrunch AI

AI-assisted digest, checked against the original source before publishing. How we work

The DeepMind spin-out's $5 billion Series C will fund clinical trials and broader drug-design ambitions, following a $2.1 billion round in May.
Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
Photo: Unsplash · free stock license

Isomorphic Labs, the AI drug-discovery company spun out of Google's DeepMind in 2021, has raised $5 billion in a Series C funding round. The company said the money will help it push its drug candidates toward clinical trials, a step that would move its work from computational design into human testing.

The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor. All of Isomorphic's existing backers also participated, including Alphabet's venture units GV and Capital G, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund. Isomorphic did not disclose its valuation; Bloomberg reported earlier this month that the lab was seeking to raise at a $50 billion valuation.

The company builds an AI drug-design engine driven by simulation models that explore different areas of chemistry. Its work builds on DeepMind's AlphaFold protein-folding model, and Isomorphic said its program has produced "positive preclinical results" in oncology and immunology. The lab has partnerships with Eli Lilly, Novartis and Johnson & Johnson. Beyond the engine itself, the new capital is earmarked for expanding into more types of medicine.

The Series C follows a $2.1 billion Series B in May and marks Isomorphic's first raise since founder and CEO Demis Hassabis stepped down as head of DeepMind to focus on drug discovery, taking a chairman role at DeepMind. Hassabis and then-DeepMind director John Jumper won the Nobel Prize in chemistry for AlphaFold, which predicts a protein's three-dimensional structure from its genetic sequence alone.

What to watch is whether Isomorphic's preclinical momentum converts into actual trial entries, and how a company of this size will be judged if trials slip or results disappoint. The unanswered valuation question also matters: a reported $50 billion mark would set a high bar for returns in a field where AI-designed drugs have yet to prove themselves in patients. Finally, expanding into "more types of medicine" raises the question of where the engine's advantage holds up beyond the oncology and immunology programs it has highlighted.

keyFacts:[

Key facts

  • • Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5.
  • • Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials | TechCrunch Isomorphic Labs.
  • • The funding was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and other investors.
  • • All of the company’s existing backers, including Alphabet’s venture divisions GV and Capital G, Thrive.

Why it matters

Takeaway: Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 Billion in a Series C funding round.

Spotted an error? Send a correction.

Get the day's AI news in one email

The Daily Epoch · 60-second read · unsubscribe anytime

Related

Models
OpenAI News1 min read

Introducing GPT-6.2 Astra and Sol

OpenAI announces GPT-6.2 Astra and Sol, targeting professional outputs, coding, computer use, and lower-cost efficiency across ChatGPT Work, Codex, and the API.